No Data
No Data
Express News | Lantern Pharma Inc - Phase 1B/2a Trial for Recurrent GBM to Start Late 2024
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Express News | Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
Lantern Appoints Piers Dixon as Head of Sales
Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And Hepatoblastoma
jimmy the trader : $China Pharma (CPHI.US)$ broths